Tpl2-IN-I
| Code | Size | Price |
|---|
| TAR-T26284-5mg | 5mg | £930.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26284-50mg | 50mg | £1,821.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26284-100mg | 100mg | £2,319.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Tpl2-IN-I is an inhibitor of tumour progression locus 2 (Tpl2) kinase.
CAS:
915009-13-1
Formula:
C21H14ClFN6
Molecular Weight:
404.83
Purity:
0.98
SMILES:
CN(c1cccnc1)c1cc2c(Nc3ccc(F)c(Cl)c3)c(cnc2cn1)C#N
References
1. Wang Y, Wang S, Kelly CP, Feng H, Greenberg A, Sun X. TPL2 is a key regulator of intestinal inflammation in C. difficile infection. Infect Immun. 2018 May 29. pii: IAI.00095-18. doi: 10.1128/IAI.00095-18. [Epub ahead of print] PubMed PMID: 29844241.
2. Alsina-Beauchamp D, Esc?s A, Fajardo P, Gonz?lez-Romero D, D?az-Mora E, Risco A, Mart?n-Serrano MA, Del Fresno C, Dominguez-Andr?s J, Aparicio N, Zur R, Shpiro N, Brown GD, Ardav?n C, Netea MG, Alemany S, Sanz-Ezquerro JJ, Cuenda A. Myeloid cell deficiency of p38?/p38? protects against candidiasis and regulates antifungal immunity. EMBO Mol Med. 2018 May;10(5). pii: e8485. doi: 10.15252/emmm.201708485. PubMed PMID: 29661910; PubMed Central PMCID: PMC5938613.
3. Chorzalska A, Ahsan N, Rao RSP, Roder K, Yu X, Morgan J, Tepper A, Hines S, Zhang P, Treaba DO, Zhao TC, Olszewski AJ, Reagan JL, Liang O, Gruppuso PA, Dubielecka PM. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-?B pathways in a model of chronic myeloid leukemia. Mol Oncol. 2018 May;12(5):630-647. doi: 10.1002/1878-0261.12186. Epub 2018 Apr 6. PubMed PMID: 29485707; PubMed Central PMCID: PMC5928369.
4. Senger K, Pham VC, Varfolomeev E, Hackney JA, Corzo CA, Collier J, Lau VWC, Huang Z, Hamidzhadeh K, Caplazi P, Peng I, Setiadi AF, Francis R, Paler-Martinez A, Kwon YC, Ramirez-Carrozzi V, Sun Y, Grigg PW, Roose-Girma M, Jeet S, Barck KH, Pham A, Ota N, Ha C, Stinson J, Guillory J, Tam L, Modrusan Z, Emson C, McKenzie BS, Townsend MJ, Carano RAD, Warming S, Vucic D, DeVoss J, Lee WP, Lill JR, Zarrin AA. The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation. Sci Signal. 2017 Apr 18;10(475). pii: eaah4273. doi: 10.1126/scisignal.aah4273. PubMed PMID: 28420753.